Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure.
IL-33
biomarker
carvedilol
heart failure
sST2
β-blocker
Journal
Clinical pharmacology : advances and applications
ISSN: 1179-1438
Titre abrégé: Clin Pharmacol
Pays: New Zealand
ID NLM: 101564865
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
04
2020
accepted:
29
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
The IL-33/ST2 pathway plays a fundamental role in the cardiovascular system and can be considered as a new therapeutic strategy for the treatment or prevention of cardiovascular diseases. ST2, as an interleukin (IL)-1 receptor family member, has transmembrane (ST2L) and soluble (sST2) isoforms. sST2 neutralizes IL-33 and thereby inhibits the cardioprotective role of IL-33/ST2L signaling pathway. Increase in sST2 level is associated with weak cardiac output and can be a predictor of mortality in heart failure (HF). Thereby, we hypothesized that there may be a relationship between the cardioprotective effects of carvedilol and sST2 and IL-3 in HF patients. sST2 and IL-33 were measured in serum of 66 individuals; 22 healthy volunteers and 44 suffering from HF; among whom 25 patients received carvedilol and the other 19 patients did not receive any β-blockers. Lack of association between serum levels of IL-33 and sST2 was observed between HF patients and healthy individuals (2.4466 ± 0.69 vs 2.6748 ± 0.33 and 3416.6 ± 1089.1 vs 2971.6 ± 792.5, respectively). Our results indicated no significant difference between sST2 and IL-33 levels in HF patients who did not receive beta-blockers and patients receiving carvedilol (P=0.59 and P=0.97). Our results showed a lack of association between serum levels of IL-33 and sST2 and HF. Moreover, the results do not confirm the cardioprotective mechanism of carvedilol by means of IL-33/sST2 pathway.
Identifiants
pubmed: 32607003
doi: 10.2147/CPAA.S256290
pii: 256290
pmc: PMC7305854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53-58Informations de copyright
© 2020 Firouzabadi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Circulation. 2008 Apr 15;117(15):1936-44
pubmed: 18378613
Curr Drug Metab. 2015;17(1):30-6
pubmed: 26537419
J Am Coll Cardiol. 1995 Apr;25(5):1154-61
pubmed: 7897129
Clin Chim Acta. 2020 Feb;501:120-130
pubmed: 31678574
Circulation. 2004 May 11;109(18):2186-90
pubmed: 15117853
J Am Coll Cardiol. 2010 Jan 19;55(3):243-50
pubmed: 20117403
Circulation. 2002 Oct 22;106(17):2194-9
pubmed: 12390947
J Am Heart Assoc. 2019 Jan 22;8(2):e008968
pubmed: 30638108
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7
pubmed: 17185418
Biochem Biophys Res Commun. 2009 Jun 19;384(1):105-9
pubmed: 19393621
J Clin Med. 2019 Feb 22;8(2):
pubmed: 30813357
J Am Coll Cardiol. 1997 Apr;29(5):1060-6
pubmed: 9120160
Pharmacol Ther. 2011 Aug;131(2):179-86
pubmed: 21356240
Am J Cardiol. 2011 Jan 15;107(2):259-67
pubmed: 21211603
Immunity. 2005 Nov;23(5):479-90
pubmed: 16286016
Nat Rev Immunol. 2010 Feb;10(2):103-10
pubmed: 20081870
J Clin Invest. 2007 Jun;117(6):1538-49
pubmed: 17492053
Nat Rev Rheumatol. 2011 Jun;7(6):321-9
pubmed: 21519352
Biochem Biophys Res Commun. 2001 Aug 3;285(5):1377-83
pubmed: 11478810
Int J Biochem Cell Biol. 2010 Feb;42(2):263-72
pubmed: 19861169
Pharmacogenomics. 2018 Sep 1;19(14):1089-1093
pubmed: 30086658
Cytokine Growth Factor Rev. 2004 Apr-Jun;15(2-3):87-95
pubmed: 15110792
Am J Cardiovasc Drugs. 2011 Jun 1;11(3):153-71
pubmed: 21619379
JACC Heart Fail. 2014 Feb;2(1):65-72
pubmed: 24622120
Rev Esp Cardiol. 2010 Oct;63(10):1171-8
pubmed: 20875357
Circulation. 2002 Dec 3;106(23):2961-6
pubmed: 12460879
Circ Heart Fail. 2009 Nov;2(6):684-91
pubmed: 19919994
Lancet. 1999 Jun 12;353(9169):2001-7
pubmed: 10376614
EMBO Rep. 2008 Oct;9(10):1006-12
pubmed: 18688256
Clin Chim Acta. 2019 Aug;495:493-500
pubmed: 31136737